# Kisspeptin: cells, hormones, eggs

> Kisspeptin: cells to fertility | aubriepeptides — Follow kisspeptin with aubriepeptides: mouse neurons, human LH and testosterone, amenorrhea, IVF egg maturation and intranasal research.

The hormone results are striking. The mouse-neuron work offers an unusually close look at the signal that precedes them.

## KISS1R and the hormone response

Kisspeptin is a family of peptides made from the KISS1 gene product. Its receptor, KISS1R or GPR54, activates GnRH neurons; GnRH then stimulates the pituitary to release LH and FSH, which support downstream sex-steroid production. The [cellular work on GnRH neurons](https://pubmed.ncbi.nlm.nih.gov/18483150/) and the [human and mouse genetics of GPR54](https://pubmed.ncbi.nlm.nih.gov/14573733/) approach that biology from different directions.

In the genetic study, loss-of-function GPR54 mutations were associated with failure of puberty and low reproductive hormones in humans. Mice lacking Gpr54 reproduced the phenotype. Those genetic consequences make a compelling case, to me, for taking the pathway seriously. Giving extra peptide to an adult asks a separate experimental question.

## Mouse neurons under observation

The 2008 electrophysiology experiment worked with **mouse GnRH neurons in vitro**, using brain slices. Kisspeptin [depolarized the neurons through a PLC–IP3–calcium pathway](https://pubmed.ncbi.nlm.nih.gov/18483150/). Depolarization is the electrical shift that helps a neuron fire. Closing potassium channels and opening non-selective cation channels were involved in that response.

At 100 nM, the reported electrical shift was 6 ± 1 mV, with firing increased by 87 ± 4% in about 75% of adult GnRH neurons. These are measurements of cells under experimental conditions. The result describes a mechanism at unusually close range; it gives no direct measurement of a person's desire.

That intimacy of scale appeals to me. Before the hormone values and fertility outcomes, there is an observable change in an individual cell.

![Glass recording pipette positioned over a brain slice beneath microscope optics](images/kisspeptin-cell-recording.webp)

*An imagined electrophysiology setup, illustrating the scale of the mouse-neuron work rather than documenting the published experiment.*

## Hormone findings in men

The 2011 human experiment used intravenous kisspeptin-10 in healthy men. A bolus [raised LH from 4.1 to 12.4 IU/L at 30 minutes](https://pubmed.ncbi.nlm.nih.gov/21632807/). In a separate continuous-infusion part of the study, mean LH rose from 5.2 to 14.1 IU/L and LH pulse frequency from 0.7 to 1.0 pulses/hour. At a higher infusion rate, serum testosterone rose from 16.6 to 24.0 nmol/L.

Those findings establish an acute hormone response under supervision. I would be asking more of the experiment than it measured if I translated that testosterone rise into a prediction about sexual satisfaction or lasting symptom relief.

## Amenorrhea; IVF triggering

In five women with hypothalamic amenorrhea, intravenous kisspeptin-54 [increased LH pulses from 1.6 to 5.0 per 8 hours](https://pubmed.ncbi.nlm.nih.gov/24517142/) compared with vehicle. At the highest continuous infusion rate the response faded during the infusion, a phenomenon called tachyphylaxis. The successful stimulation and the fading response occurred within the same research programme. Both matter to any account of sustained hormone activity.

The IVF trial had a different task. In a Phase 2 randomized study of 60 women at high risk of ovarian hyperstimulation syndrome, kisspeptin-54 [triggered oocyte maturation in 95% of women](https://pubmed.ncbi.nlm.nih.gov/26192876/). There were no cases of moderate, severe or critical OHSS in that trial. Oocytes are egg cells; maturation was the immediate job of the experimental trigger within a much larger IVF process.

A job as specific as egg maturation earns my respect. The observed absence of those OHSS cases is encouraging, while the study's size and selected population remain attached to the finding.

## Intranasal kisspeptin-54

The 2025 delivery experiment [measured LH release after intranasal kisspeptin-54](https://pubmed.ncbi.nlm.nih.gov/40215751/) in healthy men, healthy women and women with hypothalamic amenorrhea. The reported LH increases were +4.4 IU/L, +1.4 IU/L and +4.4 IU/L respectively. No adverse events were reported in the study, and the formulation was stable for up to 60 days at 4°C.

The route changes what can be attempted in research. It does not establish a home treatment or resolve the questions around repeated exposure. The hormone response is the finding to credit here.

## Kisspeptin safety

Community accounts describe increased sexual interest, emotional closeness, spontaneous erections and sometimes renewed cycle activity; others describe no perceptible change. Warmth, headache, nausea and local irritation also appear. These are **anecdotal accounts, not clinical evidence**, and they cannot establish how often an effect occurs or whether kisspeptin caused it.

Kisspeptin remains investigational, with no approved indication. The [clinical-status review published in 2025](https://pubmed.ncbi.nlm.nih.gov/38265397/) identified 29 interventional trials in searches through February 2023. The selected supervised studies here leave long-term safety, pregnancy and hormone-sensitive conditions unresolved. Their results also cannot establish the identity, purity or sterility of material outside those study settings.

Further work could give that enthusiasm firmer ground: I want repeated-exposure safety findings and replication across research centres before the clinical possibilities become easier to assess. For desire and distress specifically, the [bremelanotide trials](/pt-141) ask different questions.

---

An independent literature digest on the reproductive hormone axis and central sexual neuropharmacology — citations, not prescriptions.
